Ascendis Pharma A/S

NasdaqGS ASND

Ascendis Pharma A/S Free Cash Flow for the year ending December 31, 2023: USD -518.55 M

Ascendis Pharma A/S Free Cash Flow is USD -518.55 M for the year ending December 31, 2023, a 5.01% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Ascendis Pharma A/S Free Cash Flow for the year ending December 31, 2022 was USD -545.87 M, a -8.52% change year over year.
Ascendis Pharma A/S Free Cash Flow for the year ending December 31, 2021 was USD -503.02 M, a -40.49% change year over year.
Ascendis Pharma A/S Free Cash Flow for the year ending December 31, 2020 was USD -358.04 M, a -76.18% change year over year.
Ascendis Pharma A/S Free Cash Flow for the year ending December 31, 2019 was USD -203.23 M, a -25.54% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGS: ASND

Ascendis Pharma A/S

CEO	Mr. Jan Moller Mikkelsen
IPO Date	Jan. 28, 2015
Location	Denmark
Headquarters	Tuborg Boulevard 12
Employees	879
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Key trends

Past 5 years